Re-evaluating Long-Term Beta-Blocker Use for Heart Attack Survivors
For decades, beta-blockers have been a standard lifelong prescription to protect the hearts of heart attack survivors. However, medical professionals are now re-evaluating the necessity of long-term beta-blocker use, particularly beyond the initial year of recovery. These medications, which lower blood pressure and slow heart rate, can come with potential side effects including fatigue, dizziness, and dry mouth or eyes.
The re-evaluation of long-term beta-blocker use aims to help patients avoid unnecessary side effects and reduce costs, especially for those beyond the initial year of recovery.
Shifting Medical Guidelines
Beta-blockers have been prescribed for over 40 years to reduce the risk of further cardiovascular events in adults who had uncomplicated heart attacks. New research is now questioning this long-standing approach, leading to a potential shift in care standards. Some physicians suggest that limiting beta-blocker use to one or two years could significantly benefit patients.
The American Heart Association (AHA) and American College of Cardiology (ACC) updated their 2023 guidelines for chronic coronary disease. These updated guidelines state that long-term beta-blocker therapy is no longer recommended for patients who have not experienced a heart attack in the past year.
Dr. Manesh Patel, president-elect of the American Heart Association, noted that initial studies on beta-blockers predate many modern cardiac care advancements like angioplasty and new blood thinners, suggesting that the evidence base is evolving.
This potential shift in care standards could significantly impact the financial burden on heart attack survivors. Dr. Joseph Ravenell of NYU Langone Health highlighted the positive implications for both quality of life and health economics, as many beta-blockers, while affordable monthly, can accumulate substantial costs over a lifetime.
New Research Findings
Dr. Valentin Fuster, president of Mount Sinai Fuster Heart Hospital, indicated that a change in practice is already occurring globally, particularly for patients with good heart or ventricular function. Previous studies in the New England Journal of Medicine have shown that immediate beta-blocker use after a heart attack did not improve outcomes for certain patients with normal heart pumping function.
A new study, also published in the New England Journal of Medicine and presented at the American College of Cardiology's annual scientific session, examined low-risk adults who were stable for at least a year after a heart attack. The study found that those who stopped taking beta-blockers did not have a higher risk of death, heart attack, or hospitalization for heart failure compared to those who continued the medication.
Study Details and Implications
The study involved over 2,500 adults across 25 health centers in South Korea. Participants had a median age of 63 and had been on beta-blocker therapy for at least one year. Approximately half were assigned to discontinue beta-blockers, while the other half continued.
Over about three years of monitoring, recurrent heart attack, hospitalization for heart failure, or death occurred in:
7.2% of the discontinuation group versus 9% of the continuation group.
The study specifically noted similar rates for death (2.4% vs. 3.4%), recurrent heart attacks (2.3% vs. 2.6%), and hospitalizations for heart failure (around 2% in both groups). While blood pressure and heart rate increased in the discontinuation group, average systolic blood pressure remained below 130.
Researchers acknowledged the need for further studies in other countries, including the United States, to confirm these findings. Dr. Joo-Yong Hahn, the study's lead author, stated that for appropriately selected stable patients without heart failure or left ventricular systolic dysfunction, routine lifelong beta-blockers may not be necessary. Discontinuation can be considered through shared decision-making, especially if a patient experiences beta-blocker-related side effects.